June 12, 2009 (FinancialWire) — PuraMed Bioscience, Inc. (OTCBB: PMBS) completed their first production run of their LipiGesic(tm)-M migraine relief product for commercial resale. This will provide the company with its first opportunity to generate revenue.

As a result of this milestone, PuraMed will be attending the NACDS Marketplace Conference in Boston 6/29-7/1. NACDS Marketplace Conference is the largest and most powerful convergence of drug, food, mass, club and value retailing in the United States, if not the world (www.nacdsmarketplace.org). This conference will lay the ground work for our retail launch of LipiGesic-M.

In addition, progress continues on the production efforts for our direct response television commercial featuring LipiGesic-M. Our initial indicators suggest that our commercial will be ready for airing and test marketing no later than the beginning of the fourth quarter 2009.

In response to the achievement of this milestone and the other significant progress, Russ Mitchell, CEO said, “The completion of our first commercial run of LipiGesic-M is a significant event for PuraMed. This will move our company forward from a pre-revenue stage to a revenue generating organization. This event, when combined with our progress on the direct response commercial and the exposure at the NACDS conference indicate the dramatic progress our team has made in the last few months and should make the upcoming launch of our first product an exciting time for PuraMed.”

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.